T-4 25 - Adelphi Research

Levothyroxine sodium was first introduced in 1955 by Flint Laboratories under the brand name Synthroid. As the first synthetic thyroid hormone sold in the U.S., it quickly became the standard treatment for hypothyroidism and retained dominance in the market for decades. By the 1990s, Synthroid captured 85% of sales, generating $600 million annually. Controversy later emerged when Flint suppressed a university study showing generics had equal efficacy. Legal battles led to a 1997 publication and a $135 million settlement by Knoll Pharmaceuticals.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about T-4 25 by Adelphi Research, consult with your doctor or healthcare professional.